2026 Grant Round: Focus on Immunotherapy

Neuroblastoma Australia is pleased to announce that our 2026 Grant Round is underway. 

In 2026, our funding will focus specifically on Immunotherapy, a rapidly evolving area of research that holds enormous promise for improving outcomes for children diagnosed with neuroblastoma. Advances in immunotherapy are creating new opportunities for more targeted, less toxic treatments, offering hope for families affected by this devastating disease. 

We have invited applications from researchers with innovative ideas and a strong commitment to advancing kinder, more effective therapies for children with neuroblastoma. 

Grants of $150k will be awarded to the successful applicants at the end of 2026. 

Grant Process and Key Dates 

The 2026 Grant Round is following a two-stage application process: 

• Stage 1 – Letter of Intent (LOI) - CLOSED

All LOIs are now being reviewed by Neuroblastoma Australia’s Scientific Advisory Board and assessed against established selection criteria. 

• Stage 2 – Full Proposal 

Successful applicants will be notified on 8 June 2026 and invited to submit a full proposal. 

Further details regarding eligibility, assessment criteria, and the full timeline for the current grant process are available below:

Grant Application Details

Neuroblastoma Australia remains committed to funding high-quality research that accelerates breakthroughs and improves survival and quality of life for children diagnosed with neuroblastoma.